Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a
medical aesthetics company uniquely focused on plastic surgeons,
today announced its audited financial results for the fourth
quarter and full year ended December 31, 2020.
Ron Menezes, President and Chief Executive
Officer of Sientra, stated, “We continue to build on our strong
fourth quarter results, which were driven primarily by our
investment and market outperformance in our core breast products
segment. While the augmentation channel remains a key performance
driver, we were also able to gain market share in the hospital
channel despite pandemic related challenges faced by the
reconstruction market. Ahead of further market normalization in
2021, we remain hyper focused on expanding our hospital account
base by continuing to capitalize on customer receptivity to the
technical differentiation and compelling safety profile of our
tissue expander portfolio, grounded by AlloX2®. We also expect to
benefit in 2021 from targeted digital efforts directed towards
patients and surgeons, an expanded and more productive sales force,
and educational peer to peer initiatives that will add new accounts
and drive continued share gains."
Mr. Menezes continued, “Our 2021 performance
will also be driven by our commitment to establish a culture of
focus and accountability, with disciplined investment and execution
on commercial, product development and manufacturing initiatives
designed to drive revenue and operating leverage. Meanwhile, we
expect to reach our goal to achieve break-even contribution margin
from miraDry in 2021, as we evaluate the strategic alternatives for
the business.”
Mr. Menezes concluded, “Given our progress to
date on each of these initiatives, we currently expect breast
product segment net sales to grow in excess of 30% in the first
quarter 2021 compared to the first quarter 2020.”
Fourth Quarter 2020 Financial
Results
- Total net sales for the fourth
quarter 2020 were $22.6 million, a decrease of 2% compared to total
net sales of $23.2 million for the same period in 2019.
- Net sales for the Breast Products
segment totaled $17.9 million in the fourth quarter 2020, an
increase of 40% compared to $12.8 million for the same period in
2019 and 17% sequential growth over the quarter ending September
30, 2020.
- Net sales for the miraDry segment
totaled $4.8 million in the fourth quarter 2020, a 54% decrease
compared to $10.4 million for the same period in 2019 and 22%
sequential growth over the quarter ending September 30, 2020.
- Gross profit for the fourth quarter
2020 was $11.1 million, or 48.9% of sales, compared to gross profit
of $14.2 million, or 61.3% of sales, for the same period in
2019.
- Operating expenses for the fourth
quarter 2020 decreased by 13.1% to $28.2 million from $32.4
million, excluding $1.1 million of restructuring charges related to
Sientra’s organizational efficiency initiative, in the same period
in 2019.
- Net loss for the fourth quarter
2020 was ($21.2) million, or ($0.42) per share, compared to a net
loss of ($20.2) million, or ($0.41) per share, for the same period
in 2019.
- On a non-GAAP basis, adjusted
EBITDA loss for the fourth quarter 2020 decreased by 24.6% to
($10.5) million from ($14.0) million for the same period in
2019.
Full Year 2020 Financial
Results
- Total net sales for the full year
2020 were $71.2 million, a decrease of 14.9% compared to total net
sales of $83.7 million for the same period in 2019.
- Net sales for the Breast Products
segment totaled $55.0 million in the full year 2020, an increase of
18.6% compared to $46.4 million for the full year 2019.
- Net sales for the miraDry segment
totaled $16.2 million in the full year 2020, a 56.5% decrease
compared to $37.3 million for the full year 2019.
- Gross profit for the full year 2020
was $38.9 million, or 54.7% of sales, compared to gross profit of
$50.7 million, or 60.6% of sales, for the full year 2019.
- Operating expenses for the full
year 2020 decreased by 29.2% to $109.2 million from $154.3 million
for the full year 2019.
- Net loss for the full year 2020 was
($89.9) million, or ($1.79) per share, compared to a net loss of
($106.8) million, or ($2.63) per share, for the full year
2019.
- On a non-GAAP basis, adjusted
EBITDA loss for the full year 2020 decreased by 35.4% to ($47.0)
million from ($72.8) million for the full year 2019.
- Net cash and cash equivalents as of
December 31, 2020 were $55.0 million, compared to $63.5 million as
of September 30, 2020. The cash balance as of December 31, 2020
does not include net proceeds from the closing of the Company’s
public offering of common stock on February 11, 2021 of
approximately $39.1 million.
Full Year 2021 Financial
Outlook
For full year 2021, the Company expects to achieve total net
sales of $78 million to $84 million, representing growth of 10% to
18% compared to net sales of $71.2 million in 2020.
- Anticipates Breast Products net
sales of $70 to $74 million, representing growth of 27% to 35% over
2020; and
- Anticipates miraDry net sales of $8
to $10 million.
Conference Call
Sientra will hold a conference call today, March
11, 2021 at 4:30 pm ET to discuss third quarter results. The
dial-in numbers are 844-464-3933 for domestic callers and
765-507-2612 for international callers. The conference ID is
3371629. A live webcast of the conference call will be available on
the Investor Relations section of the Company's website at
www.sientra.com. The webcast will be archived on the website
following the completion of the call.
Use of Non-GAAP Financial
Measures
Sientra has supplemented its US GAAP net
income (loss) with a non-GAAP measure of Adjusted EBITDA.
Management believes that this non-GAAP financial measure provides
useful supplemental information to management and investors
regarding the performance of the Company, facilitates a more
meaningful comparison of results for current periods with previous
operating results, and assists management in analyzing future
trends, making strategic and business decisions and establishing
internal budgets and forecasts. A reconciliation of non-GAAP
Adjusted EBITDA to GAAP net income (loss), the most directly
comparable GAAP measure, is provided in the schedule below.
There are limitations in using this non-GAAP
financial measure because it is not prepared in accordance with
GAAP and may be different from non-GAAP financial measures used by
other companies. This non-GAAP financial measure should not be
considered in isolation or as a substitute for GAAP financial
measures. Investors and potential investors should consider
non-GAAP financial measures only in conjunction with Sientra’s
financial statements prepared in accordance with GAAP and the
reconciliations of the non-GAAP financial measure provided in the
schedule below.
About Sientra
Headquartered in Santa Barbara, California,
Sientra is a medical aesthetics company uniquely focused on plastic
surgeons. The Company offers a suite of products designed to make a
difference in patients' lives by enhancing their body image,
growing their self-esteem, and restoring their confidence. Sientra
has developed a broad portfolio of products with technologically
differentiated characteristics, supported by independent laboratory
testing and strong clinical trial outcomes. The Company’s Breast
Products Segment includes its Sientra round and shaped breast
implants, the first fifth generation breast implants approved by
the FDA for sale in the United States, its ground-breaking Allox2®
breast tissue expander with patented dual-port and integral drain
technology, and BIOCORNEUM® the #1 performing, preferred and
recommended scar gel of plastic surgeons(*). The Company’s miraDry
Segment, comprised of its miraDry® system, is approved for sale in
over 56 international markets and is the only non-surgical,
FDA-cleared device indicated for the permanent reduction of
underarm sweat and hair and may also reduce odor.
Sientra uses its investor relations website
to publish important information about the Company, including
information that may be deemed material to investors. Financial and
other information about Sientra is routinely posted and
is accessible on the Company’s investor relations website
at www.sientra.com.
(*) Data on file
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, based on management’s current assumptions and
expectations of future events and trends, which affect or may
affect the Company’s business, strategy, operations or financial
performance, and actual results may differ materially from those
expressed or implied in such statements due to numerous risks and
uncertainties. Forward-looking statements are made only as of the
date of this release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’
‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue,
‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or
the negative of those terms, and similar expressions that convey
uncertainty of future events or outcomes are intended to identify
estimates, projections and other forward-looking statements.
Forward-looking statements may include information concerning the
impact of the COVID-19 pandemic on the Company and its operations,
the Company’s possible or assumed future results of operations,
including descriptions of the Company’s revenues, profitability,
anticipated growth rates, market outlook, impact of marketing
programs and overall business strategy. Such statements are subject
to risks and uncertainties, including the scope and duration of the
COVID-19 pandemic, the Company’s ability to recapture delayed
procedures resulting from the COVID-19 pandemic, the positive
reaction from plastic surgeons and their patients to Sientra’s
Breast Products, the positive reaction from plastic surgeons and
patients to Sientra’s marketing, sales and educational programs,
the ability to execute on the Company’s commercial, product
development and manufacturing initiatives, the ability of the
Company to drive revenue and operating leverage, the ability to
meet consumer demand, the growth of the sale of bioTips in its
miraDry segment, and the Company’s ability to manage its operating
expenses and cash balance. Additional factors that could cause
actual results to differ materially from those contemplated in this
press release can be found in the Risk Factors section of Sientra’s
public filings with the Securities and Exchange Commission. All
statements other than statements of historical fact are
forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’
‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue,
‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or
the negative of those terms, and similar expressions that convey
uncertainty of future events or outcomes are intended to identify
estimates, projections and other forward-looking statements. You
are cautioned not to place undue reliance on these forward-looking
statements, and such estimates, projections and other
forward-looking statements speak only as of the date they were
made, and, except to the extent required by law, the Company
undertakes no obligation to update or review any estimate,
projection or forward-looking statement. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in the Company’s business.
ContactInvestor Relations805-679-8885
Sientra, Inc. |
|
Consolidated Statements of Operations |
|
(In thousands, except per share and share
amounts) |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Year Ended |
|
|
|
December 31, |
|
|
December 31, |
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
Net sales |
|
$ |
22,644 |
|
|
$ |
23,210 |
|
|
$ |
71,241 |
|
|
$ |
83,699 |
|
Cost of goods sold |
|
|
11,569 |
|
|
|
8,971 |
|
|
|
32,302 |
|
|
|
33,012 |
|
Gross profit |
|
|
11,075 |
|
|
|
14,239 |
|
|
|
38,939 |
|
|
|
50,687 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing |
|
|
14,939 |
|
|
|
19,202 |
|
|
|
52,553 |
|
|
|
80,189 |
|
Research and development |
|
|
2,564 |
|
|
|
4,011 |
|
|
|
10,311 |
|
|
|
13,537 |
|
General and administrative |
|
|
10,691 |
|
|
|
9,233 |
|
|
|
38,191 |
|
|
|
46,771 |
|
Restructuring |
|
|
(87 |
) |
|
|
1,083 |
|
|
|
1,762 |
|
|
|
1,083 |
|
Impairment |
|
|
— |
|
|
|
— |
|
|
|
6,432 |
|
|
|
12,674 |
|
Total operating expenses |
|
|
28,107 |
|
|
|
33,529 |
|
|
|
109,249 |
|
|
|
154,254 |
|
Loss from operations |
|
|
(17,032 |
) |
|
|
(19,290 |
) |
|
|
(70,310 |
) |
|
|
(103,567 |
) |
Other income (expense), net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
3 |
|
|
|
323 |
|
|
|
206 |
|
|
|
1,406 |
|
Interest expense |
|
|
(2,162 |
) |
|
|
(1,292 |
) |
|
|
(9,451 |
) |
|
|
(4,568 |
) |
Change in fair value of derivative liability |
|
|
(2,050 |
) |
|
|
— |
|
|
|
(10,470 |
) |
|
|
— |
|
Other income (expense), net |
|
|
37 |
|
|
|
46 |
|
|
|
111 |
|
|
|
(55 |
) |
Total other income (expense), net |
|
|
(4,172 |
) |
|
|
(923 |
) |
|
|
(19,604 |
) |
|
|
(3,217 |
) |
Loss before income taxes |
|
|
(21,204 |
) |
|
|
(20,213 |
) |
|
|
(89,914 |
) |
|
|
(106,784 |
) |
Income tax |
|
|
33 |
|
|
|
34 |
|
|
|
33 |
|
|
|
34 |
|
Net loss |
|
$ |
(21,237 |
) |
|
$ |
(20,247 |
) |
|
$ |
(89,947 |
) |
|
$ |
(106,818 |
) |
Basic and diluted net loss per
share attributable to common stockholders |
|
$ |
(0.42 |
) |
|
$ |
(0.41 |
) |
|
$ |
(1.79 |
) |
|
$ |
(2.63 |
) |
Weighted average outstanding
common shares used for net loss per share attributable to common
stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
50,462,124 |
|
|
|
49,506,169 |
|
|
|
50,233,175 |
|
|
|
40,654,272 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sientra, Inc. |
|
Condensed Consolidated Balance Sheets |
|
(In thousands) |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
December 31, |
|
|
|
2020 |
|
|
2019 |
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
54,967 |
|
|
$ |
87,608 |
|
Accounts receivable, net |
|
|
23,503 |
|
|
|
27,548 |
|
Inventories, net |
|
|
48,648 |
|
|
|
39,612 |
|
Prepaid expenses and other current assets |
|
|
2,154 |
|
|
|
2,489 |
|
Total current assets |
|
|
129,272 |
|
|
|
157,257 |
|
Property and equipment, net |
|
|
13,106 |
|
|
|
12,314 |
|
Goodwill |
|
|
9,202 |
|
|
|
9,202 |
|
Other intangible assets, net |
|
|
9,387 |
|
|
|
17,390 |
|
Other assets |
|
|
8,011 |
|
|
|
8,241 |
|
Total assets |
|
$ |
168,978 |
|
|
$ |
204,404 |
|
Liabilities and
Stockholders’ Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Current portion of long-term debt |
|
$ |
4,670 |
|
|
$ |
6,508 |
|
Accounts payable |
|
|
6,504 |
|
|
|
9,352 |
|
Accrued and other current liabilities |
|
|
32,389 |
|
|
|
32,551 |
|
Customer deposits |
|
|
17,905 |
|
|
|
13,943 |
|
Sales return liability |
|
|
9,192 |
|
|
|
8,116 |
|
Total current liabilities |
|
|
70,660 |
|
|
|
70,470 |
|
Long-term debt, net of current
portion |
|
|
60,500 |
|
|
|
38,248 |
|
Derivative liability |
|
|
26,570 |
|
|
|
— |
|
Deferred and contingent
consideration |
|
|
2,350 |
|
|
|
5,177 |
|
Warranty reserve and other
long-term liabilities |
|
|
9,455 |
|
|
|
8,627 |
|
Total liabilities |
|
|
169,535 |
|
|
|
122,522 |
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
Total stockholders’ equity |
|
|
(557 |
) |
|
|
81,882 |
|
Total liabilities and stockholders’ equity |
|
$ |
168,978 |
|
|
$ |
204,404 |
|
|
|
|
|
|
|
|
|
|
Sientra, Inc. |
|
Condensed Consolidated Statements of Cash
Flows |
|
(In thousands) |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2020 |
|
|
2019 |
|
Cash flows from operating
activities: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(89,947 |
) |
|
$ |
(106,818 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
|
|
|
Impairment |
|
|
6,432 |
|
|
|
12,674 |
|
Depreciation and amortization |
|
|
4,094 |
|
|
|
3,524 |
|
Provision for doubtful accounts |
|
|
4,423 |
|
|
|
2,298 |
|
Provision for warranties |
|
|
1,271 |
|
|
|
929 |
|
Provision for inventory |
|
|
3,601 |
|
|
|
2,626 |
|
Fair value adjustments to derivative liability |
|
|
10,470 |
|
|
|
— |
|
Fair value adjustments of other liabilities held at fair value |
|
|
96 |
|
|
|
969 |
|
Amortization of debt discount and issuance costs |
|
|
4,347 |
|
|
|
359 |
|
Stock-based compensation expense |
|
|
8,344 |
|
|
|
12,478 |
|
Payments of contingent consideration liability in excess of
acquisition-date fair value |
|
|
— |
|
|
|
(1,968 |
) |
Other non-cash adjustments |
|
|
375 |
|
|
|
290 |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(378 |
) |
|
|
(7,320 |
) |
Inventories |
|
|
(12,808 |
) |
|
|
(10,921 |
) |
Prepaid expenses, other current assets and other assets |
|
|
935 |
|
|
|
(8,513 |
) |
Accounts payable, accrueds, and other liabilities |
|
|
(6,420 |
) |
|
|
6,694 |
|
Customer deposits |
|
|
3,961 |
|
|
|
4,008 |
|
Sales return liability |
|
|
1,077 |
|
|
|
2,068 |
|
Legal settlement payable |
|
|
— |
|
|
|
(410 |
) |
Net cash used in operating activities |
|
|
(60,127 |
) |
|
|
(87,033 |
) |
Cash flows from investing
activities: |
|
|
|
|
|
|
|
|
Purchase of property and equipment |
|
|
(4,037 |
) |
|
|
(4,071 |
) |
Business acquisitions, net of cash and restricted cash
acquired |
|
|
— |
|
|
|
(17,943 |
) |
Net cash used in investing activities |
|
|
(4,037 |
) |
|
|
(22,014 |
) |
Cash flows from financing
activities: |
|
|
|
|
|
|
|
|
Proceeds from option exercises and employee stock purchase
plan |
|
|
865 |
|
|
|
1,341 |
|
Net proceeds from issuance of common stock |
|
|
263 |
|
|
|
107,734 |
|
Payments related to tax witholding on
vested restricted stock units (RSUs) |
|
|
(1,791 |
) |
|
|
(3,064 |
) |
Gross borrowings under the Term Loan |
|
|
— |
|
|
|
5,000 |
|
Repayments under the Term Loan |
|
|
(25,000 |
) |
|
|
— |
|
Gross borrowings under the PPP loan |
|
|
6,652 |
|
|
|
— |
|
Gross borrowings under the Revolving Loan |
|
|
— |
|
|
|
22,296 |
|
Repayment of the Revolving Loan |
|
|
(6,508 |
) |
|
|
(15,788 |
) |
Net proceeds from issuance of the Convertible Note |
|
|
60,000 |
|
|
|
— |
|
Payments of contingent consideration up to acquisition-date fair
value |
|
|
— |
|
|
|
(5,766 |
) |
Deferred financing costs |
|
|
(2,958 |
) |
|
|
(1,997 |
) |
Net cash provided by financing activities |
|
|
31,523 |
|
|
|
109,756 |
|
Net increase (decrease) in cash, cash equivalents and restricted
cash |
|
|
(32,641 |
) |
|
|
709 |
|
Cash, cash equivalents and
restricted cash at: |
|
|
|
|
|
|
|
|
Beginning of period |
|
|
87,951 |
|
|
|
87,242 |
|
End of period |
|
$ |
55,310 |
|
|
$ |
87,951 |
|
|
|
|
|
|
|
|
|
|
Reconciliation of cash, cash
equivalents, and restricted cash to the consolidated balance
sheets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
54,967 |
|
|
$ |
87,608 |
|
Restricted cash included in other assets |
|
|
343 |
|
|
|
343 |
|
Total cash, cash equivalents and restricted cash |
|
$ |
55,310 |
|
|
$ |
87,951 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sientra, Inc. |
|
Reconciliation of Net Loss to Non-GAAP Adjusted
EBITDA |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Year Ended |
|
|
|
December 31, |
|
|
December 31, |
|
Dollars, in
thousands |
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
Net loss, as reported |
|
$ |
(21,237 |
) |
|
$ |
(20,247 |
) |
|
$ |
(89,947 |
) |
|
$ |
(106,818 |
) |
Adjustments to net loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest (income) expense and other, net |
|
|
2,122 |
|
|
|
923 |
|
|
|
9,134 |
|
|
|
3,217 |
|
Provision for income taxes |
|
|
33 |
|
|
|
34 |
|
|
|
33 |
|
|
|
34 |
|
Depreciation and amortization |
|
|
1,098 |
|
|
|
986 |
|
|
|
4,094 |
|
|
|
3,524 |
|
Fair value adjustments to contingent consideration |
|
|
68 |
|
|
|
454 |
|
|
|
135 |
|
|
|
1,044 |
|
Fair value adjustments to derivative liability |
|
|
2,050 |
|
|
|
— |
|
|
|
10,470 |
|
|
|
— |
|
Stock-based compensation |
|
|
2,879 |
|
|
|
2,797 |
|
|
|
8,344 |
|
|
|
12,478 |
|
Restructuring |
|
|
(87 |
) |
|
|
1,083 |
|
|
|
1,762 |
|
|
|
1,083 |
|
One-time severance charges |
|
|
2,539 |
|
|
|
— |
|
|
|
2,539 |
|
|
|
— |
|
Impairment |
|
|
— |
|
|
|
— |
|
|
|
6,432 |
|
|
|
12,674 |
|
Total adjustments to net loss |
|
|
10,702 |
|
|
|
6,277 |
|
|
|
42,943 |
|
|
|
34,054 |
|
Adjusted EBITDA |
|
$ |
(10,535 |
) |
|
$ |
(13,970 |
) |
|
$ |
(47,004 |
) |
|
$ |
(72,764 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Year Ended |
|
|
|
December 31, |
|
|
December 31, |
|
As a Percentage of
Revenue** |
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
Net loss, as reported |
|
|
(93.8 |
%) |
|
|
(87.2 |
%) |
|
|
(126.3 |
%) |
|
|
(127.6 |
%) |
Adjustments to net loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest (income) expense and other, net |
|
|
9.4 |
% |
|
|
4.0 |
% |
|
|
12.8 |
% |
|
|
3.8 |
% |
Provision for income taxes |
|
|
0.1 |
% |
|
|
0.1 |
% |
|
|
0.0 |
% |
|
|
0.0 |
% |
Depreciation and amortization |
|
|
4.8 |
% |
|
|
4.2 |
% |
|
|
5.7 |
% |
|
|
4.2 |
% |
Fair value adjustments to contingent consideration |
|
|
0.3 |
% |
|
|
2.0 |
% |
|
|
0.2 |
% |
|
|
1.2 |
% |
Fair value adjustments to derivative liability |
|
|
9.1 |
% |
|
|
0.0 |
% |
|
|
14.7 |
% |
|
|
0.0 |
% |
Stock-based compensation |
|
|
12.7 |
% |
|
|
12.1 |
% |
|
|
11.7 |
% |
|
|
14.9 |
% |
Restructuring |
|
|
(0.4 |
%) |
|
|
4.7 |
% |
|
|
2.5 |
% |
|
|
1.3 |
% |
One-time severance charges |
|
|
11.2 |
% |
|
|
0.0 |
% |
|
|
3.6 |
% |
|
|
0.0 |
% |
Impairment |
|
|
0.0 |
% |
|
|
0.0 |
% |
|
|
9.0 |
% |
|
|
15.1 |
% |
Total adjustments to net loss |
|
|
47.3 |
% |
|
|
27.0 |
% |
|
|
60.3 |
% |
|
|
40.7 |
% |
Adjusted EBITDA |
|
|
(46.5 |
%) |
|
|
(60.2 |
%) |
|
|
(66.0 |
%) |
|
|
(86.9 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
** Adjustments
may not add to the total figure due to rounding |
|
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Apr 2023 to Apr 2024